|Bid||3.60 x 900|
|Ask||3.68 x 1100|
|Day's Range||3.41 - 4.57|
|52 Week Range||2.22 - 9.15|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.50|
Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Phase 3 trial in treatment-naïve EGFR mutation-positive NSCLC patients targeted to.
CK-101 is the company’s most advanced candidate intended for non-small cell lung cancer (NSCLC) and addresses some of the shortcomings of previous generation drugs. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is an orally administered therapy under development for lung cancer patients whose tumors carry EGFR mutations, including the T790M resistance mutation. Preliminary results of the trial were accepted as a late-breaking submission.
6 of 8 pts ORR in treatment-naïve EGFR mutation-positive NSCLC patients. Well-tolerated with unremarkable safety profile; No DLTs or related SAEs. Phase 3 trial in treatment-naïve EGFR mutation-positive ...
NEW YORK, Aug. 30, 2018-- Checkpoint Therapeutics, Inc., a Fortress Biotech company, today announced that James F. Oliviero, President and Chief Executive Officer of Checkpoint, will present a company ...
NASDAQ:CKPT Checkpoint Therapeutics (NASDAQ:CKPT) announced today that it will present results from the CK-101 Phase I/II program at the World Conference on Lung Cancer on Monday, September 24 in Toronto, ...
NEW YORK, Aug. 13, 2018-- Checkpoint Therapeutics, Inc., a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for ...
Checkpoint Therapeutics, Inc. (CKPT) delivered earnings and revenue surprises of 34.29% and -65.68%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, Aug. 07, 2018-- Checkpoint Therapeutics, Inc., a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for ...
Last August, National Securities Corp analyst Jonathan Aschoff was bullish on Avenue Therapeutics Inc (ATXI.O), a fledgling biotechnology company with no revenue and one drug in clinical trials. Nearly a year later, Avenue shares are down 36 percent, at about $4. A few months earlier, Aschoff had waxed equally optimistic about another biotech venture, Checkpoint Therapeutics Inc (CKPT.O), with several cancer drugs in various stages of development.
It was only eight years ago, at the June 2010 American Society of Clinical Oncology conference, when Bristol Myers presented groundbreaking data showing a significant survival advantage in melanoma for ipilimumab, the first successful checkpoint blockade inhibitor (CBI). This announcement followed years of failures in the immuno-oncology space with highly touted compounds such as Sanofi’s iniparib, GSK’s Elesclomol and many others falling by the wayside.
Although overlooked by the investors, Checkpoint Therapeutics (CKPT) looks well positioned for a solid gain evident from its favorable Zacks rank and positive estimate revision.
Stock Monitor: Corvus Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 19, 2018 / Active-Investors.com has just released a free research report on Checkpoint Therapeutics, Inc. (NASDAQ: CKPT ...
Checkpoint Therapeutics Inc (NASDAQ: CKPT ), a nano-cap therapeutics company that focuses on developing anti-cancer agents , has lost more than half of its value over the past few months but some analysts ...